secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001104659-24-067485
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance reports $363M cash, 50+ ATCs onboard for Amtagvi; frontline melanoma data shows 65.2% ORR
--------------------------------------------------------------------------------

- Cash position of ~$363M as of 3/31/2024; 600+ employees and 50+ payers covering 200M+ lives have approved Amtagvi for at least one patient.
- 50 Authorized Treatment Centers onboarded by 5/28/2024; targeting ~70 by end of 2024; 100+ patients enrolled by 5/9/2024.
- EU submission for Amtagvi planned in 2Q2024; UK and Canada submissions in 2H2024.
- Phase 2 frontline melanoma (IOV-COM-202 Cohort 1A) results: ORR 65.2%, CR 30.4%, median PFS not reached at 21.7 months follow-up.
- Registrational TILVANCE-301 Phase 3 trial for frontline melanoma randomized first patient in 2Q2023; dual primary endpoints ORR and PFS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924067485/0001104659-24-067485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924067485/tm2416237d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-067485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer